AP NEWS

Opium (Opioid) Addiction - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Opium (Opioid) Addiction - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 6, 2, 18, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Overview Therapeutics Development Therapeutics Assessment Companies Involved in Therapeutics Development Drug Profiles Dormant Projects Discontinued Products Product Development Milestones

Companies Featured

Adapt Pharma Ltd. Addex Therapeutics Ltd. Aoxing Pharmaceutical Company Inc. BioCorRx Inc. BioDelivery Sciences International Inc. Camurus AB Fab’entech SA Indivior PLC Insys Therapeutics Inc. iX Biopharma Ltd. Novartis AG Omeros Corp. Opiant Pharmaceuticals Inc. Orexo AB Pfizer Inc. Relmada Therapeutics Inc. Serina Therapeutics Inc. Syntropharma Ltd. Titan Pharmaceuticals Inc. Zynerba Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wbrvrg/opium_opioid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005434/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Addiction Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 10:16 AM/DISC: 09/17/2018 10:16 AM

http://www.businesswire.com/news/home/20180917005434/en

AP RADIO
Update hourly